Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Abstract Background To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). Methods SAKK 26/10 is a multicenter, prospective cohort study of early breast cancer patients: Eligibility: R0-res...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Bernhard C. Pestalozzi, Christoph Tausch, Konstantin J. Dedes, Christoph Rochlitz, Stefan Zimmermann, Roger von Moos, Ralph Winterhalder, Thomas Ruhstaller, Andreas Mueller, Katharina Buser, Markus Borner, Urban Novak, Catrina Uhlmann Nussbaum, Bettina Seifert, Martin Bigler, Vincent Bize, Simona Berardi Vilei, Christoph Rageth, Stefan Aebi, The Swiss Group for Clinical Cancer Research (SAKK)
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2017-04-01
coleção:	BMC Cancer
Assuntos:	ER-positive early breast cancer Adjuvant treatment recommendation Multigene expression profiling Recurrence score Oncotype DX
Acesso em linha:	http://link.springer.com/article/10.1186/s12885-017-3261-1
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!